Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes

Thiazolidinediones reduce urinary albumin excretion and may prevent the development of renal injury. We evaluated the long-term effects of rosiglitazone on the progression of renal dysfunction in patients with type 2 diabetes mellitus. We enrolled patients with type 2 diabetes mellitus who initially...

Full description

Saved in:
Bibliographic Details
Published in:The Korean journal of internal medicine 2009, 24(3), , pp.227-232
Main Authors: Kim, Mee Kyoung, Ko, Seung-Hyun, Baek, Ki-Hyun, Ahn, Yu-Bae, Yoon, Kun-Ho, Kang, Moo-Il, Lee, Kwang-Woo, Song, Ki-Ho
Format: Article
Language:English
Subjects:
Adult
Aged
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - physiopathology
Diabetic Nephropathies - prevention & control
Female
Glomerular Filtration Rate
Humans
Hypoglycemic Agents - therapeutic use
Kidney - physiopathology
Male
Middle Aged
Original
Retrospective Studies
Thiazolidinediones - therapeutic use
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thiazolidinediones reduce urinary albumin excretion and may prevent the development of renal injury. We evaluated the long-term effects of rosiglitazone on the progression of renal dysfunction in patients with type 2 diabetes mellitus. We enrolled patients with type 2 diabetes mellitus who initially had normal or mildly impaired renal function, defined as an estimated glomerular filtration rate (eGFR) of 60-120 mL/min per 1.73 m2, and normoalbuminuria. Patients were divided into two groups according to their use of rosiglitazone during 3 years of follow-up: those treated with rosiglitazone (rosiglitazone group, n=52) and those treated without rosiglitazone (control group, n=85). Progression of renal dysfunction was defined as a decrease in eGFR of >or=9 mL/min per 1.73 m2 after 3 years. A greater difference was observed in the decrease in eGFR between the rosiglitazone and control groups after 3 years (3.8+/-9.9 vs. 12.6+/-10.5 mL/min per 1.73 m2, p
ISSN:1226-3303
2005-6648
DOI:10.3904/kjim.2009.24.3.227